The Impact of Combination Therapy with Rivaroxaban and Acetylsalicylic Acid in Patients with Coronary Heart Disease on the Achievement of the Target for Reducing Mortality from Cardiovascular Diseases of the Federal Project "Fight against Cardiovascular Diseases"
Aim. To assess the outcomes of combination therapy with rivaroxaban and acetylsalicylic acid (ASA) in patients with stable coronary artery disease (CAD) and a high risk of thrombotic events on the set targets of Ministry of Health for reduction of cardiovascular mortality in Russia.Material and meth...
Saved in:
Main Authors: | M. V. Zhuravleva, A. V. Panov, A. R. Kuksenok |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2022-03-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Subjects: | |
Online Access: | https://www.rpcardio.online/jour/article/view/2673 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure
by: M. V. Zhuravleva, et al.
Published: (2022-01-01) -
Evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator “reduction of mortality from diseases of the circulatory system” in 2022-2024
by: M. V. Zhuravleva, et al.
Published: (2022-01-01) -
Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery disease
by: N. V. Pogosova, et al.
Published: (2019-12-01) -
Main directions of prophylaxis of untimely mortality from cardiovascular diseases
by: A. T. Adamyan, et al.
Published: (2009-04-01) -
Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases
by: M. V. Zhuravleva, et al.
Published: (2020-11-01)